Partnering

Partnering Opportunities
Our lead project on the use of megalin antagonists for protection against aminoglycoside-mediated nephrotoxicity is now available for partnering. This project will be of particular interest to pharmaceutical companies with products in the aminoglycoside market.

Research collaborations
Drug-induced nephrotoxicity: ReceptIcon is a major player in the field of megalin research and its know-how is protected by a large number of patent applications. Research in this area aims at 1) the identification of therapeutic drugs other than aminoglycosides that accumulate in the kidney via this receptor and, 2) in the development of novel antagonists to block renal uptake and nephrotoxicity of such compounds. This project will be particularly relevant for companies commercializing nephrotoxic drugs such as antiinfectiva (e.g., vancomycin, amphoterizin B), antineoplastic drugs (e.g. cisplatin, ifosfamide), antisense oligonucleotides, and immunosuppressants (cyclosporine).

Steroid hormone metabolism: ReceptIcon's R&D efforts aim at the identification of cellular pathways responsible for delivery of steroid hormones to steroid-dependent tumors of the breast and prostate, and on the design of antagonists to block such pathways for anti-tumor therapy.

In both areas, ReceptIcon is open for collaborations with public and industrial research partners.